{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:02:55Z","timestamp":1789401775222,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108365","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:17:53Z","timestamp":1786022273000},"page":"108365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108365_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108365_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108365_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186225","article-title":"and Lotte Bjerre Knudsen awarded Lasker prize for pioneering work on GLP-1","volume":"134","author":"Ardehali","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108365_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-5448.2000.010108.x","article-title":"Synthesis, secretion and biological actions of the glucagon-like peptides","volume":"1","author":"Lovshin","year":"2000","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.phrs.2026.108365_bib5","first-page":"867","article-title":"A gastric inhibitory polypeptide. II. The complete amino acid sequence","volume":"49","author":"Brown","year":"1971","journal-title":"Complet. amino Acid. Seq. Can. J. Biochem."},{"key":"10.1016\/j.phrs.2026.108365_bib6","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108365_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108365_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108365_bib10","doi-asserted-by":"crossref","first-page":"12826","DOI":"10.1016\/S0021-9258(18)51561-1","article-title":"Complete sequences of glucagon-like peptide-1 from human and pig small intestine","volume":"264","author":"Orskov","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108365_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Vilsb\u00f8ll","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2026.108365_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diacare.18.5.715","article-title":"Glucagon and its family revisited","volume":"18","author":"Lef\u00e8bvre","year":"1995","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108365_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1210\/edrv-12-3-252","article-title":"Structure and pancreatic expression of the insulin and glucagon genes","volume":"12","author":"Philippe","year":"1991","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2026.108365_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1054\/npep.1999.0053","article-title":"Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress","volume":"33","author":"van Dijk","year":"1999","journal-title":"Neuropeptides"},{"key":"10.1016\/j.phrs.2026.108365_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fendo.2018.00387","article-title":"The origin and understanding of the incretin concept","volume":"9","author":"Rehfeld","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2026.108365_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.phrs.2026.108365_bib18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.metabol.2015.05.012","article-title":"Incretin-based therapies for obesity treatment","volume":"64","author":"de Mello","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2026.108365_bib19","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","article-title":"The molecular basis of G protein-coupled receptor activation","volume":"87","author":"Weis","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2026.108365_bib20","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1042\/BST20210431","article-title":"Structure determination of GPCRs: cryo-EM compared with X-ray crystallography","volume":"49","author":"Garc\u00eda-Nafr\u00eda","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.phrs.2026.108365_bib21","first-page":"2","article-title":"Structure, function, pharmacology, and therapeutic potential of the G protein, G\u03b1\/q,11","volume":"24","author":"Kamato","year":"2015","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib22","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.apsb.2026.01.023","article-title":"Distinctive molecular architectures of Gq- and Gi-coupled GLP-1 receptors","volume":"16","author":"Zhou","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.108365_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.aaz5346","article-title":"Structural basis of Gs and Gi recognition by the human glucagon receptor","volume":"367","author":"Qiao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108365_bib24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/obr.70148","article-title":"GLP-1 receptor agonists and weight loss: a critical review of mechanisms","author":"Rutigliani","year":"2026","journal-title":"Obes. Rev."},{"key":"10.1016\/j.phrs.2026.108365_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1532076","article-title":"The role of GIPR in food intake control","volume":"16","author":"James-Okoro","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2026.108365_bib27","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/dom.16279","article-title":"Time in range-A new gold standard in type 2 diabetes research?","volume":"27","author":"Goshrani","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J3G883","article-title":"The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Nikfar","year":"2012","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108365_bib29","first-page":"161","article-title":"Evolution of exenatide as a diabetes therapeutic","volume":"9","author":"Bhavsar","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.phrs.2026.108365_bib30","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108365_bib31","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1074\/jbc.272.7.4108","article-title":"Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard","volume":"272","author":"Chen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108365_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41467-021-27760-0","article-title":"Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation","volume":"13","author":"Deganutti","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108365_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell."},{"key":"10.1016\/j.phrs.2026.108365_bib34","doi-asserted-by":"crossref","first-page":"D425","DOI":"10.1093\/nar\/gkae1065","article-title":"GPCRdb in 2025: adding odorant receptors, data mapper, structure similarity search and models of physiological ligand complexes","volume":"53","author":"Herrera","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108365_bib35","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrd1828","article-title":"Exenatide","volume":"4","author":"Davidson","year":"2005","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108365_bib37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40265-015-0420-z","article-title":"Exenatide extended-release: An updated review of its use in type 2 diabetes mellitus","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108365_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2710.2010.01180.x","article-title":"Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes","volume":"36","author":"Ryan","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib39","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108365_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-026-01427-1","article-title":"The evolving landscape of obesity pharmacotherapy","volume":"25","author":"Petersen","year":"2026","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.phrs.2026.108365_bib41","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108365_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s12325-021-01637-6","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: A network meta-analysis","volume":"38","author":"Jiang","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2026.108365_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1060028017726348","article-title":"The clinical use of a fixed-dose combination of insulin degludec and liraglutide (Xultophy 100\/3.6) for the treatment of type 2 diabetes","volume":"52","author":"Harris","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108365_bib45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/jdi.70293","article-title":"Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis","volume":"17","author":"Wang","year":"2026","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.phrs.2026.108365_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.phrs.2026.108365_bib47","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","article-title":"Dulaglutide: first global approval","volume":"74","author":"Sanford","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108365_bib48","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/dom.16276","article-title":"Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study","volume":"27","author":"Haluz\u00edk","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib49","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"a comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug. Des. Devel Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2026.108365_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1060028019889064","article-title":"Oral Semaglutide: First-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"54","author":"Cowart","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108365_bib52","article-title":"A Review of the oral semaglutide in adults with overweight or obesity (OASIS) trials evaluating oral semaglutide (Wegovy) for chronic weight management in adults with overweight or obesity","volume":"18","author":"Ojinna","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2026.108365_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108365_bib55","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s13300-025-01794-9","article-title":"Real-world effectiveness of tirzepatide versus semaglutide on HbA1c and weight in patients with type 2 diabetes","volume":"16","author":"Hoog","year":"2025","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2026.108365_bib57","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108365_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2024.100321","article-title":"Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pasqualotto","year":"2024","journal-title":"Metabol. Open."},{"key":"10.1016\/j.phrs.2026.108365_bib59","article-title":"Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials","volume":"17","author":"Wu","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108365_bib60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide Phase 2 Obesity Trial Investigators, Triple-hormone-receptor agonist retatrutide for obesity - A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.58347\/tml.2026.1755a","article-title":"Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss","volume":"68","author":"No authors listed","year":"2026","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib62","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"drug-like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108365_bib63","doi-asserted-by":"crossref","first-page":"eadp5765","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib64","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib65","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108365_bib66","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/ijms27031409","article-title":"Orforglipron: A comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes","volume":"27","author":"Kansakar","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108365_bib67","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108365_bib68","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13300-025-01829-1","article-title":"Rewriting diabetes therapy: How incretin modulation is transforming cardiovascular and renal outcomes","volume":"17","author":"Miramontes-Gonz\u00e1lez","year":"2026","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2026.108365_bib69","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/bmj-2026-372161","article-title":"Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis","volume":"394","author":"Nong","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2026.108365_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMra2500106","article-title":"GLP-1 receptor agonists","volume":"394","author":"Rosen","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib71","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11606-026-10195-y","article-title":"Coverage is the key to realizing the promise of semaglutide","volume":"41","author":"Gasoyan","year":"2026","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2026.11253","article-title":"CMS' GLP-1 bridge demonstration-questions and potential consequences","author":"Sachs","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108365_bib73","doi-asserted-by":"crossref","first-page":"qcag079","DOI":"10.1093\/ehjqcco\/qcag079","article-title":"Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"12","author":"Ahmed","year":"2026","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"10.1016\/j.phrs.2026.108365_bib74","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/oby.70169","article-title":"Weight loss with GLP-1 agonists in nondiabetic adults: systematic review and network meta-analysis","volume":"34","author":"Lim","year":"2026","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.phrs.2026.108365_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108365_bib76","doi-asserted-by":"crossref","DOI":"10.3122\/jabfm.2025.250158R1","article-title":"Emerging and off-label uses of glucagon-like peptide-1 receptor agonists (GLP1-RA) and dual GIP\/GLP1-Ras","volume":"39","author":"Morello","year":"2026","journal-title":"J. Am. Board. Fam. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.25141","article-title":"Glucagon-like peptide-1 receptor agonists and fragility fracture risk in type 2 diabetes","volume":"9","author":"Hamad","year":"2026","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.phrs.2026.108365_bib78","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ajhp\/zxag115","article-title":"National trends in prescription drug expenditures and projections for 2026","volume":"83","author":"Tichy","year":"2026","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.phrs.2026.108365_bib79","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2026.100199","article-title":"The landscape of 10 global innovative drug targets 2015-2024","volume":"4","author":"Tan","year":"2026","journal-title":"Innov. Med."},{"key":"10.1016\/j.phrs.2026.108365_bib80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600280X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600280X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:07:00Z","timestamp":1789398420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600280X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S104366182600280X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108365","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108365"}}